 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp.
On August 4th, Dynavax reported 2nd Quarter June 2021 earnings of $0.02 per share on revenue of $52.8 million. The consensus estimate was a loss of $0.04 per share on revenue of $41.6 million. Revenue grew 1,877.8% on a year-over-year basis. The next report is on November 3rd.
Shares of Dynavax jumped 25% on Sep 22 after its partner, Clover Biopharmaceuticals announced positive data from a pivotal study evaluating the clover’s COVID-19 vaccine candidate.
Clover was evaluating its vaccine candidate, SCB-2019, adjuvanted with Dynavax's CpG 1018 adjuvant in a phase II/III study — SPECTRA. Data from the study demonstrated that immunization with the candidate led to overall efficacy of 100% against severe COVID-19 and hospitalization, and 84% against moderate-to-severe COVID-19 caused by currently leading strains of coronavirus, including Delta, Gamma, and Mu variants.
Shares have formed a bullish "pennant" and are expected to move higher from current levels.
Entry Point: $19.75
Stop Loss: $18.75
Trading Range: $3.58 to $20.66
Target Price: $22.00
